Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Molecular Mind is an AI-driven biotechnology company specializing in the computational design and optimization of proteins. Founded in 2022 by Dr. Xu Feng, the former Chief Scientist of Baidu and a pioneer in AI-driven biological research, the company utilizes its proprietary MoleculeOS platform to streamline the drug discovery process. The platform integrates advanced deep learning algorithms with biological insights to predict protein structures, interactions, and properties with high precision. Molecular Mind aims to address complex challenges in healthcare and synthetic biology by facilitating the creation of novel protein therapeutics and high-performance industrial enzymes. The company has secured significant venture capital from prominent investors to advance its AI-native biological research and development pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Molecular Mind.